期刊文献+

大鼠SOCS3基因重组腺病毒载体的构建及转染血管平滑肌细胞后的表达 被引量:2

Construction of Rat SOCS3 Recombinant Adenovirus Vector and Its Expression in Rat Primary Vascular Smooth Muscle Cells
暂未订购
导出
摘要 目的构建携带大鼠SOCS3基因的重组腺病毒载体并转染大鼠血管平滑肌细胞,评价其转染效果,为血管增殖性疾病转基因治疗的实验研究奠定基础。方法用BamHⅠ和EcoRⅠ将目的基因pUC57-Simple-rSOCS3及腺病毒穿梭载体pYr-adshuttle-4(带GFP标记)行双酶切。回收酶切质粒的目的片段进行连接,产物转化至DH5α感受态。提取质粒酶切鉴定正确后测序。通过LR体外同源重组将rSOCS3表达框构建至pAd/PL-DEST腺病毒表达载体上。将腺病毒线性化后转染HEK293细胞包装腺病毒,PCR鉴定此腺病毒中是否含有rSOCS3基因。放大培养并收集病毒,TCD法测定病毒滴度。将此病毒感染大鼠血管平滑肌细胞,荧光显微镜观察感染效率,real-time PCR及免疫印迹检测SOCS3mRNA及蛋白表达。结果 rSOCS3腺病毒穿梭质粒酶切鉴定正确,测序与rSOCS3基因库中的序列完全相符。PCR鉴定pAd/PL-DEST腺病毒表达载体成功携带目的基因rSOCS3。TCD法测定的最终滴度为2×1010pfu/mL。荧光显微镜观察此病毒感染血管平滑肌细胞的效率在80%以上,real-time PCR及免疫印迹检测结果显示血管平滑肌细胞中SOCS3mRNA及蛋白表达明显上调。结论成功构建携带大鼠SOCS3基因的腺病毒载体,并在血管平滑肌细胞中高表达,为血管增殖性疾病转基因治疗的实验研究奠定了基础,具有一定的应用价值。 Objective To construct the recombinant adenovirus vector carrying rat SOCS3 gene and assess its transfection efficiency in vascular smooth muscle cells(VSMCs).Methods The rat SOCS3 plasmid(pUC57-Simple-rSOCS3)and advenovirus shuttle plasmid(pYr-adshuttle-4)containing green fluorescent protein(GFP)reporter gene were cleaved by restriction endonuclease BamHⅠ and EcoR Ⅰ.The target gene fragments were connected together to generate a recombinant plasmid pYr-adshuttle-4-rSOCS3 that was transfected into E.coli DH5α.The plasmid was confirmed to be constructed as expectation by enzyme digestion and sequencing.The plasmid pYr-adshuttle-4-rSOCS3 and type 5 adenovirus backbone plasmid pAd/PL-DEST were reconstructed by homologous recombination processes to obtain rat SOCS3 recombinant adenovirus vector which named pYrAd-rSOCS3.The plasmid pYrAd-rSOCS3 was linearized by PacⅠ and subsequently transfected into HEK293 cells for packaging and amplification.After purification,virus titer was determined by tissue culture infectious dose 50(TCID50).Polymerase chain reaction(PCR)was used to confirm the existence of recombinant rat SOCS3 gene.The primary rat VSMCs were infected by pYrAd-rSOCS3.After 24 h,the expression of GFP was observed under the fluorescent microscopy.SOCS3 mRNA and protein expression was detected by using real-time PCR and Western blot.Results Restriction endonuclease and PCR analysis demonstrated that the recombinant adenovirus vector was constructed correctly.hEF1a and CMV promoter existed in the expression vector.The virus titer reached 2×1010 pfu/mL.Transfection efficiency of recombinant adenovirus in VSMCs was more than 80%.Real-time PCR and Western blot revealed that SOCS3 mRNA and protein expression was up-regulated significantly in the infected VSMCs.Conclusion In this study,we successfully constructed a recombinant adenovirus vector that carries rat SOCS3 gene and can be helpful for further research on the effects and mechanisms of the SOCS3 gene on the vascular proliferation diseases.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2012年第5期556-561,共6页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
关键词 SOCS3 腺病毒载体 转基因治疗 血管平滑肌细胞 血管增殖性疾病 SOCS3 adenovirus vector transgenic therapy vascular smooth muscle cells vascular proliferative disease
  • 相关文献

参考文献17

  • 1Dzau V J,Braun-Dullaeus R C,Sedding D G. Vascular prolif-eration and atherosclerosis: new perspectives and therapeutic strategies[J]. Nat Med, 2002,8(11) :1249-1256.
  • 2Mitra A K, Gangahar M D, Gagraual K D. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft irltimal hyperplasia[J]. Immunol Cell Biol, 2006,84 (2) : 115-124.
  • 3O' Shea J J, Murray P J. Cytokine signaling modules in in- flammatory responses[J]. Immunity,2008,28(4)447 487.
  • 4Croker B A,Kiu H,Icholson S E. Socs regulation of the JAK/ STAT signalling pathway[J]. Semin Cell Dev Biol,2008,19 (4) :414-422.
  • 5Tan J C, Rabkin R. Suppressor of cytokine signaling in health and diseaserJ]. Pediatr Nephrol, 2005,20 (5) : 567-575.
  • 6Croker B A,Metcalf D,Robb L,et al. Socs3 is a critical physi- ological negative regulator of G CSF signalling and emergency granulopoiesis[J]. Immunity,2004,20(2) :153-165.
  • 7Kerbs D L, Hilton D J. SOCS proteins: Negative regulators of eytokine signaling[J]. Stem Ce11,2001,19(5) :378 387.
  • 8Siemens D, Crist S, Austin J C, et al. Comparison of viral vec- tors : Gene transfer efficiency and tissue speeificity in a bladder cancer mode[J]. J Urol, 2003,170(3) : 979-984.
  • 9Dimitriou I D,Clemenza L, Scotter A J, et al. Putting out the fire:Coordinated suppression of the innate and adaptive im- mune systems by socsl and SOCS3 proteins [J]. Immunol Rev. 2008. 224 (1), 265-283.
  • 10Dalpke A, Heeg K, Bartz H, et al. Regulation of innate immu- nity by suppressor of eytokine signaling(SOCS)proteins[J]. Immunobiology,2008,213(3/4) :225 235.

二级参考文献32

  • 1Start R, Willson TA, Viney EM, et al. A family of cytokine inducible inhibitors of signalling. Nature, 1997, 387: 917-921.
  • 2Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature, 1997, 387: 921-924.
  • 3Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature, 1997, 387: 924-929.
  • 4Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci, 2000, 113: 2813-2819.
  • 5Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells, 2001, 19: 378-387.
  • 6Alexander WS. Suppressors of cytokine signaling (SOCS) in the immune system. Nat Rev Immunol, 2002, 2: 410-416.
  • 7Ronn SG, Hansen JA, Lindberg K, et al. The effect of suppressor of cytokine signaling 3 on GH signaling in B-cells. Mol Endocrinol, 2002, 16(9): 2124-2134.
  • 8Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem, 2000, 275: 15985-15991.
  • 9Krebs DL, Hilton DJ. A new role for SOCS in insulin action: suppressor of cytokine signaling. Sci STKE, 2003, 169: 6.
  • 10Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab, 2006, 17: 365-371.

共引文献10

同被引文献31

  • 1陈统一,张键.周围神经损伤与再生研究的回顾与展望[J].国外医学(骨科学分册),2004,25(5):259-261. 被引量:8
  • 2张西峰,朱盛修.周围神经损伤手术修复方法的进展[J].中国现代手术学杂志,1996,1(1):62-64. 被引量:2
  • 3Buchholz PM, Buchholz AP, Augustin AJ. Antivascular endothelial growth factor as an approach for macular edema [ J ]. Dev Ophthalmo1,2010,46 ( 1 ) : 111 - 112.
  • 4Bazan-Peregrino M, Seymour LW, Harris AL. Gene therapy targeting to tumor endothelium [ J]. Cancer Gene Ther,2007,14 (2) :117 -127.
  • 5Obeid M, Tesniere A, GhiringheUi F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death [ J ]. Nat Med, 2007,13(1) :54 -61.
  • 6Dreieicher E, Beck KF, Lazaroski S, et al. Nitric oxide inhibits glomerilar TGF-β singaling via SMOC-1 [ J]. J Am Soc Nephrol, 2009,20 (9) : 1963 - 1974.
  • 7Choi YA, Lim J, Kim KM, et al. Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation [ J ]. J Proteome Res, 2010,9 ( 6 ) : 2946 - 2956.
  • 8Brcllier F, Ruggiero S ,Zwolanek D,et al. SMOC1 is a tenascin-C interacting protein over-expressed in brain tumors [ J ]. Matrix Biol,2011,30 ( 3 ) :225 - 233.
  • 9孔令海.显微外科技术修复周围神经损伤[J].医学创新研究,2007,4(32):24-25.
  • 10Skoulis TG,Lovice D,von Fricked K,et al.Nerve expansion.The optimal answer for the short nerve gap.Behavioral analysis[J].Clin Orthop Relat Res,1995,314:84-94.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部